Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001649989-26-000005
Filing Date
2026-06-03
Accepted
2026-06-03 18:03:16
Documents
1
Period of Report
2026-06-02

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 4  
1 PRIMARY DOCUMENT primary_doc.xml 4 3102
  Complete submission text file 0001649989-26-000005.txt   4701
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Issuer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA 4TH FLOOR, PO BOX 142904 AMMAN M2 11844
Business Address
Haddadin Yezan Munther (Reporting) CIK: 0001718004 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37759 | Film No.: 261062422